Clinical trials: Epigenetic Changes
Mild Cognitive Impairment, Metabolic Syndrome
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation
The study explores whether selective memory complaints (SMC), mild cognitive impairment (MCI) and the comorbidity of Metabolic Syndrome symptomatic of peripheral and cerebral hypo-metabolism with corresponding epigenetic shifts…
- Trial name
- NCT03319173
- Testing
- Dietary intervention
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Bristlecone Health, Inc.
Major Depressive Disorder
Epigenetic Regulation of BDNF in Major Depression
The investigators will (1) detect the associations between brain-derived neurotrophic factor (BDNF) DNA methylation, histone modification, depressive symptoms, suicidal behavior and antidepressant responses in major depressive…
- Trial name
- NCT01182103
- Where
- Taiwan
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Breast Neoplasms
Reversing Therapy Resistance With Epigenetic-Immune Modification
The investigators propose a randomized two arm trial, using Simon's 2-stage design, in ER+ patients with therapy resistant breast cancer to test the optimal sequence and dosing of epigenetic immune priming in hormone therapy…
- Trial name
- NCT02395627
- Testing
- Tamoxifen, Vorinostat, Pembrolizumab
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of California, San Francisco
Metastatic Melanoma
Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
The purpose of this study is to treat metastatic melanoma with a combination of standard chemotherapy (decitabine and Temozolomide in a dose escalation scheme) with an study drug called panobinostat.
- Trial name
- NCT00925132
- Testing
- Temozolomide, Decitabine, Panobinostat
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Iowa
Adenosquamous Carcinoma of the Pancreas
Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)
Background: Pancreatic cancer is one of the most lethal types of cancer. American Society for Clinical Pathology (ASCP) is a highly aggressive type of pancreatic cancer. It is very rare.
- Trial name
- NCT04896073
- Testing
- Minnelide, ECG, CT/MRI
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)